1. Scrip
  3. >>Executives On The Move

Appointments: Gyroscope, Urovant, Horizon, Modus, Allied Minds And Adherium

 
• By Lubna Ahmed

This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.

Gyroscope Therapeutics, a company focused on retinal diseases, has appointed Soraya Bekkali CEO, chief medical officer and director of its board. Before Gyroscope, Bekkali was senior vice president and chief medical officer of Lysogene SAS and previously, she was global head of the ophthalmology business unit at Sanofi, where she spent 10 years in various positions.

Keith A. Katkin has been elected Urovant Sciences' CEO and most recently, he was president and CEO of Avanir Pharmaceuticals Inc. Katkin joined Avanir in 2005 as senior...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Innate Pharma And Alloy Therapeutics Get New CEOs

Pascal Soriot, CEO of AstraZeneca, joins Agilent Technologies' board, plus Zealand Pharma acquires chief development officer from UCB Biopharma.

Executives On The Move: Capricor Therapeutics Acquires Chief Medical Officer From Pfizer, Galapagos And Cellarity Get A New CEO, And More

Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

More from Leadership

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list